Vimian Group AB’s Q4 2024 Outperformance: Strong Growth in Specialty Pharma and Diagnostics Drives Positive Outlook

Analyst Adela Dashian of Jefferies maintained a Buy rating on Vimian Group AB (0V0 – Research Report), retaining the price target of SEK50.00.

Adela Dashian’s rating is based on Vimian Group AB’s strong financial performance in the fourth quarter of 2024, which surpassed market expectations. The company reported a significant 15% organic growth, with net sales increasing by 27% year-over-year, reaching EUR 104.9 million. This growth was primarily driven by robust performance in their Specialty Pharma, Veterinary Services, and Diagnostics segments.
Furthermore, the adjusted EBITA saw a year-over-year rise to EUR 24.6 million, although the EBITA margin did decline due to strategic investments. These investments include R&D capitalization, marketing in the US orthopedics market, and expansion efforts in their Diagnostics division. Despite some challenges, such as those affecting the MedTech sector in the US, Dashian’s positive outlook reflects confidence in Vimian’s strategic direction and growth potential.